Acute Myeloid Leukaemia M6

Other names

Acute? myeloid leukaemia M6 has been known by several names. The common names are acute? erythroid leukaemia (AEL) and erythroleukaemia. Older literature may use Di Guglielmo disease/syndrome after early descriptions in the 1910s–1920s. In the FAB (French-American-British) classification it is AML-M6. When the marrow is almost entirely immature erythroid cells, modern systems (WHO 5th edition and the International Consensus Classification, 2022) call it pure erythroid leukaemia (PEL). When there is a mix of erythroid and myeloid cells with dysplasia, many cases are now classified as AML or MDS/AML with myelodysplasia-related changes or by a defining mutation (for example AML with mutated TP53). PMCCollege of American Pathologists

Types

Historic FAB types (you may still see these names in charts or older papers):

1. Erythroid/myeloid (M6a): ≥50% marrow cells are erythroid precursors and ≥30% of the remaining non-erythroid cells are myeloblasts.

2. Pure erythroid leukaemia (M6b): ≥80% of marrow cells are immature erythroid precursors (pronormoblasts/early erythroblasts) with little or no myeloid component. PMC+1

3. Erythroid/Myeloid (classic FAB M6a): A high proportion of immature red cell precursors plus myeloblasts in the marrow. Symptoms come from low counts of all lines. Now often re-classified based on genetic features and blast %.

4. Pure Erythroid Leukaemia (classic FAB M6b): Almost all marrow cells are very immature erythroid precursors with very few myeloblasts. This subtype is rare, aggressive, and strongly linked to complex chromosome changes (commonly TP53 mutations).

5. Therapy-related AML with erythroid predominance: AML that appears after prior chemotherapy or radiation for another cancer. It often behaves aggressively and may qualify for specific regimens (e.g., liposomal anthracycline/cytarabine) and transplant if eligible.

6. AML with myelodysplasia-related changes (AML-MR) with erythroid predominance: Occurs on top of a prior bone marrow disorder like MDS. It often carries high-risk genetic changes and lower response to standard therapy.

7. Genetically defined AML with erythroid bias: Some modern labels are based on gene mutations (e.g., TP53, IDH1/2, FLT3, RUNX1, ASXL1, DNMT3A). The erythroid look in the marrow may be strong, but the genetic label drives treatment choices.

Modern reclassification (why the name changed):

Evidence showed biology and genes matter more than the old percentages. The WHO 2022 and ICC 2022 systems therefore keep pure erythroid leukaemia (PEL) as a distinct pattern but reassign many “M6” cases to AML with myelodysplasia-related features or AML with mutated TP53, depending on blasts and mutations. This change improves diagnosis? and prognosis? grouping. College of American PathologistsPMC

Causes

1. Older age. AML risk increases with age as DNA damage builds up. Many reported M6/PEL cases are in older adults. Age itself is a risk factor. NCBI

2. Male sex. AML is slightly more common in males, which is seen across subtypes. PMC

3. Cigarette smoking. Smoke contains benzene and other carcinogens that raise AML risk. Smoking is a consistent, modifiable risk factor. Cancer Research UK

4. Benzene exposure. Long-term exposure at work or from solvents raises AML risk. Benzene is strongly linked to leukaemia. Cancer.org+1

5. Prior chemotherapy (alkylators). Past treatment with alkylating agents can lead to therapy-related AML/MDS years later. Cancer.gov

6. Prior chemotherapy (topoisomerase II inhibitors). Drugs such as etoposide can trigger AML after a shorter latency. City of Hope

7. Radiation exposure. High-dose medical or environmental radiation increases AML risk. NCBI

8. Previous radiotherapy for cancer. Radiation used to treat another cancer can cause therapy-related AML. Cancer.gov

9. Pre-existing myelodysplastic syndrome (MDS). Some patients with MDS progress to AML with erythroid predominance. Modern rules call many of these MDS/AML rather than “M6.” College of American Pathologists

10. Inherited predisposition (RUNX1, DDX41, GATA2, TP53, etc.). Rare germline mutations raise lifetime AML risk; TP53 syndromes are relevant to PEL biology. NCBI

11. Down syndrome and other constitutional disorders. Several congenital? syndromes raise AML risk (though DS is classically linked to M7, it still increases myeloid leukaemia propensity). Verywell Health

12. Family history of AML. Rare but real; some families carry leukaemia-predisposition genes. Verywell Health

13. Exposure to other organic solvents/pesticides. Some industrial chemicals beyond benzene are associated with AML in occupational studies. PMC

14. Obesity. Several studies link higher BMI with increased AML risk, likely via infection?, or irritation, often causing pain?, swelling?, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation? and hormonal pathways. PMC

15. Prior bone marrow injury/infection?, or irritation, often causing pain?, swelling?, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation?. Chronic? marrow stress may set the stage for clonal changes that evolve into AML. (General mechanism summarized in AML reviews.) NCBI

16. Autoimmune? disease treated with cytotoxics. Past exposure to cytotoxic drugs for autoimmune? conditions can contribute to later AML. NCBI

17. Chronic? tobacco-smoke/vehicle exhaust exposure. These contain benzene and related compounds and are linked to AML risk. University of Rochester Medical Center

18. Advanced marrow clonal haematopoiesis (CHIP). Age-related clones can acquire further hits and transform to AML. (General AML mechanism.) NCBI

19. Prior AML or other haematologic disease. Patients treated for a prior blood cancer can later develop therapy-related AML. Cancer.gov

20. Unknown/de novo. Many people have no identifiable cause; random DNA errors accumulate and trigger AML without a clear exposure. NCBI

Symptoms

1. Tiredness and weakness?. Anaemia reduces oxygen delivery, so daily tasks feel hard. Wikipedia

2. Shortness of breath on exertion. Low haemoglobin limits exercise tolerance. Wikipedia

3. Pale skin. Anaemia makes the skin and inner eyelids look pale. Wikipedia

4. Frequent infections. Low normal white cells and poor function increase infections and fevers. Wikipedia

5. Fever? or night sweats. infection?, or irritation, often causing pain?, swelling?, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">Inflammation? and infection are common in AML. Wikipedia

6. Easy bruising. Low platelets cause bruises with minor bumps. Wikipedia

7. Bleeding gums or nosebleeds. Platelet? shortage and fragile vessels lead to mucosal bleeding. Wikipedia

8. Tiny red spots (petechiae). These pinpoint spots are small skin bleeds from low platelets. Wikipedia

9. Bone or joint pain?. The packed marrow and fast cell turnover can be painful. Wikipedia

10. Weight loss? and poor appetite. Cancer-related infection?, or irritation, often causing pain?, swelling?, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation? can suppress appetite. Wikipedia

11. Swollen spleen or liver. These organs can enlarge when they filter leukaemia cells. Wikipedia

12. pain? in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">Headache? or confusion (rare emergency). Very high white counts can slow blood flow (leukostasis). Health

13. Chest pain? or breathlessness at rest (emergency). Leukostasis or infection can cause serious chest symptoms. Health

14. Skin pallor with yellow tint. Haemolysis and high turnover may raise bilirubin, giving a sallow tone. Wikipedia

15. General “flu-like” illness that does not improve. Many people feel unwell for weeks due to low blood counts and inflammation. Wikipedia

Diagnostic tests

A) Physical examination

1. Vital signs and fever check. Looks for fever, fast heart rate, and low oxygen. Infection is common in AML. It also sets a baseline for urgent care. Cancer.gov

2. Skin and mucosa exam for pallor, bruises, petechiae. These clues point to anaemia and low platelets from marrow failure. Wikipedia

3. Mouth and gum inspection. Bleeding or infections in the mouth are frequent when counts are low. Wikipedia

4. Abdominal palpation for spleen and liver. Enlargement suggests cell buildup or infection and helps guide imaging. Wikipedia

5. Neurologic screen. Headache, confusion, or focal signs may suggest leukostasis or bleeding and prompt urgent imaging. Health

B) “Manual” bedside or microscope-based assessments

6. Manual differential on the blood smear. A trained scientist or doctor looks at a stained smear, counting cells by hand. In erythroid-rich AML, you can see nucleated red cell precursors, blasts, anisopoikilocytosis, and teardrop cells. This directs urgent action and further testing. Medscape

7. Manual reticulocyte estimate. A quick stain can show whether the marrow is making mature red cells. In erythroid leukaemia, reticulocytes are often low because abnormal blasts crowd out normal maturation. Wikipedia

8. Bone marrow aspirate smear review. A pathologist manually examines marrow cells on a slide. In PEL, ≥80% of marrow cells are immature erythroid forms (pronormoblasts/early erythroblasts). PMC

C) Laboratory and pathological tests

9. Full blood count (FBC/CBC). Shows anaemia, low platelets, and variable white counts. It is the usual first clue to AML. Cancer.gov

10. Peripheral blood smear (pathologist review). Confirms blasts and nucleated red cells; assesses cell shapes and any schistocytes. Essential for classifying the process. Medscape

11. Bone marrow biopsy (core). Shows overall marrow architecture, cellularity, and sheets of immature erythroid cells in pure erythroid leukaemia. This is critical for final diagnosis. Bone Marrow Journal

12. Cytochemical stains (PAS, MPO, Sudan Black). In erythroid leukaemia, PAS typically shows coarse “block-positive” staining in erythroblasts, while myeloperoxidase and Sudan Black are usually negative in the erythroid component. This pattern supports erythroid lineage. PMCASH Publications

13. Flow cytometry (immunophenotyping). Erythroid blasts often express CD71 (transferrin receptor) and may express glycophorin A, E-cadherin, and CD117; myeloid markers are limited. These panels help separate erythroid from other AML subtypes. PMCOxford Academic

14. E-cadherin and glycophorin A immunohistochemistry on biopsy. E-cadherin is frequently positive in immature erythroblasts; glycophorin A tends to highlight more mature erythroid cells. Together, they confirm erythroid lineage when flow is difficult. Hilaris Publisher

15. Conventional cytogenetics (karyotype) and FISH. Many PEL/AEL cases have complex karyotypes and TP53 abnormalities (often 17p loss). Finding these changes refines the modern diagnosis. MDPI

16. Molecular testing (NGS panel). Looks for mutations (e.g., TP53) that now define categories such as AML with mutated TP53 in the ICC. Results affect prognosis and modern naming. College of American Pathologists

D) Electrodiagnostic tests

17. Electrocardiogram (ECG). Not diagnostic of leukaemia, but important at baseline and if there are chest symptoms or electrolyte issues from tumour lysis; it helps detect arrhythmias or ischaemia that may complicate care. (General AML practice.) Cancer.gov

18. Electroencephalogram (EEG) when neurologic events occur. If seizures or altered consciousness appear (e.g., from CNS bleeding or leukostasis), EEG helps assess brain activity and guide emergency care. (Supportive, not disease-defining.) Health

E) Imaging studies

19. Chest X-ray or CT chest. These look for pneumonia or bleeding when fever, cough, or low oxygen are present, and for leukostasis-related complications. Imaging supports urgent management. Cancer.gov

20. Ultrasound abdomen or CT abdomen/pelvis. Helps size the spleen and liver, check for organ infiltration, and find complications like infection or bleeding. This is supportive information alongside marrow tests. Cancer.gov

Non-pharmacological treatments

Goal: support the person, prevent complications, and prepare for/optimize medical treatment.

Physiotherapy & physical rehabilitation

1. Energy-conserving activity pacing
   Description: Plan day in short blocks with rests; prioritize important tasks; sit rather than stand when possible.
   Purpose: Reduce exhaustion from anaemia and treatment.
   Mechanism: Balances oxygen demand with limited red cell supply.
   Benefits: Less fatigue, better function, fewer crashes.

2. Gentle aerobic walking program
   Description: 5–20 minutes of slow walking, 3–5 days/week, adjusted to blood counts and symptoms.
   Purpose: Maintain endurance and mood.
   Mechanism: Gradual cardiovascular conditioning without overtaxing anaemic body.
   Benefits: Better stamina, sleep, and appetite.

3. Light resistance exercise with bands
   Description: 1–2 sets, very light bands, major muscle groups; pause during fevers or very low counts.
   Purpose: Preserve muscle mass during treatment.
   Mechanism: Stimulates muscle protein synthesis at safe intensity.
   Benefits: Strength retention, easier daily tasks.

4. Breathing physiotherapy
   Description: Diaphragmatic breathing, incentive spirometry, coughing techniques.
   Purpose: Prevent chest infections during neutropenia.
   Mechanism: Improves ventilation and mucus clearance.
   Benefits: Fewer respiratory complications.

5. Range-of-motion and stretching
   Description: Daily gentle stretches for neck, shoulders, hips, calves.
   Purpose: Reduce stiffness from bed rest and steroids.
   Mechanism: Keeps joints flexible; maintains fascia glide.
   Benefits: Comfort, posture, lower pain.

6. Balance and fall-prevention drills
   Description: Safe supervised standing balance tasks; remove home tripping risks.
   Purpose: Avoid injuries and bleeding when platelets are low.
   Mechanism: Neuromuscular practice; hazard control.
   Benefits: Fewer falls, more confidence.

7. Lymphatic and circulatory support
   Description: Ankle pumps, calf squeezes, gentle mobility frequently.
   Purpose: Reduce swelling, encourage venous return during inactivity.
   Mechanism: Muscle pump action aids circulation.
   Benefits: Comfort, reduced clot risk.

8. Posture and back-care training
   Description: Ergonomic sitting/standing, micro-breaks, lumbar support.
   Purpose: Ease bone pain and deconditioning aches.
   Mechanism: Reduces paraspinal strain.
   Benefits: Less pain, better breathing.

9. Skin protection and pressure relief
   Description: Repositioning every 2 hours; cushions; moisturizers.
   Purpose: Prevent pressure injury and infection gateways.
   Mechanism: Improves blood flow to skin; maintains barrier.
   Benefits: Fewer sores and infections.

10. Oral care routine training
    Description: Soft brush, alcohol-free rinse, floss only if platelets safe; treat mouth sores early.
    Purpose: Cut infection and bleeding risk.
    Mechanism: Lowers oral bacterial load; protects mucosa.
    Benefits: Easier eating; fewer infections.

11. Fatigue self-management education
    Description: Recognize triggers, schedule rests, use checklists.
    Purpose: Gain control over unpredictable fatigue.
    Mechanism: Behavioral planning conserves energy.
    Benefits: More independence, less frustration.

12. Sleep hygiene coaching
    Description: Fixed sleep/wake times, no screens before bed, quiet dark room.
    Purpose: Improve sleep disturbed by stress and steroids.
    Mechanism: Resets circadian rhythm.
    Benefits: Better mood, immunity, and coping.

13. Safety with low platelets training
    Description: Avoid high-impact activities; use soft toothbrush; electric razor.
    Purpose: Reduce bleeding incidents.
    Mechanism: Minimizes tissue trauma.
    Benefits: Fewer emergency visits.

14. Neutropenia precautions in daily movement
    Description: Hand hygiene, mask in crowded places, avoid gyms during nadir.
    Purpose: Prevent infections when white cells low.
    Mechanism: Limits exposure to pathogens.
    Benefits: Fewer fevers, uninterrupted therapy.

15. Return-to-function goal setting
    Description: Small, measurable rehab goals co-designed with therapist.
    Purpose: Keep motivation during long treatment.
    Mechanism: Behavioral activation and positive reinforcement.
    Benefits: Clear progress, better quality of life.

Mind-body

16. Guided imagery & relaxation audio
    Purpose/Mechanism: Lowers sympathetic stress signals, eases nausea and pain perception.
    Benefits: Calmer mood, better appetite and sleep.

17. Mindfulness-based stress reduction (short daily practice)
    Mechanism: Attention training reduces rumination and anxiety spikes.
    Benefits: Better coping, less fatigue from stress.

18. Brief cognitive-behavioral skills
    Mechanism: Reframes catastrophic thoughts; builds problem-solving habits.
    Benefits: Improved adherence to care, less distress.

19. Breath-paced meditation (4-7-8 or box breathing)
    Mechanism: Vagal stimulation, heart-rate variability improvement.
    Benefits: Rapid calm before procedures or chemo days.

20. Support groups (in-person/online)
    Mechanism: Peer modeling and shared practical tips.
    Benefits: Reduced isolation; better information flow.

Educational / lifestyle therapies

21. Infection-prevention skills training
    Mechanism: Hand hygiene, food safety, mask use; early fever reporting.
    Benefits: Fewer severe infections.

22. Medication literacy coaching
    Mechanism: Understand names, timing, interactions; keep a med list.
    Benefits: Safer use; fewer missed doses.

23. Nutrition during neutropenia education
    Mechanism: Safe food choices and adequate calories/protein.
    Benefits: Better healing, fewer GI infections.

24. Financial and navigation counseling
    Mechanism: Links to assistance programs, transport, lodging.
    Benefits: Lower stress and improved treatment continuity.

25. Caregiver training
    Mechanism: Teaches monitoring, safe hygiene, emergency signs.
    Benefits: Safer home care and earlier problem detection.

Note: All physical activity must be adapted to your counts, symptoms, and clinician guidance. Pause activity with fever, severe anaemia, chest pain, or active bleeding.

Drug treatments

Drugs are listed with class, typical use, purpose, basic mechanism, common side effects. Doses are examples—your oncology team individualizes dosing based on your body, kidneys/liver, genetics, and trial protocols.

1. Cytarabine (Ara-C) — antimetabolite
   Use/dose (examples): Core AML drug. In “7+3,” continuous infusion for 7 days; in consolidation, high-dose cycles are common if eligible.
   Purpose/mechanism: Blocks DNA synthesis in blasts.
   Common effects: Low counts, mouth sores, nausea; at high doses, eye irritation (prevent with steroid eye drops), cerebellar toxicity risk (dose- and age-related).

2. Daunorubicin — anthracycline
   Use: Combined with cytarabine (“7+3”) for induction.
   Mechanism: Intercalates DNA, inhibits topoisomerase II; generates free radicals.
   Effects: Low counts, hair loss, mucositis; cardiotoxicity risk (cumulative dose), red-colored urine for 1–2 days.

3. Idarubicin — anthracycline
   Use: Alternative to daunorubicin in induction.
   Mechanism/effects: Similar to daunorubicin; myelosuppression, mucositis, cardiotoxicity risk; sometimes different schedules.

4. CPX-351 (liposomal daunorubicin + cytarabine)
   Class: Dual-drug liposome.
   Use: Therapy-related AML or AML with myelodysplasia-related changes.
   Mechanism: Fixed 5:1 molar ratio improves delivery to marrow.
   Effects: Prolonged low counts and infections; similar anthracycline risks.

5. Azacitidine — hypomethylating agent (HMA)
   Use: For older/frail adults or molecularly defined settings; often combined with venetoclax.
   Mechanism: DNA hypomethylation reactivates silenced genes; cytotoxic at higher doses.
   Effects: Low counts, GI upset, injection-site reactions.

6. Decitabine — HMA
   Use: Similar to azacitidine; IV schedules vary.
   Mechanism/effects: As above; myelosuppression, infections; sometimes preferred in specific protocols.

7. Venetoclax — BCL-2 inhibitor
   Use: With HMA (azacitidine or decitabine) for adults ineligible for intensive chemo.
   Mechanism: Triggers programmed cell death in AML blasts.
   Effects: Tumour lysis syndrome risk at start (careful ramp-up), low counts, infections; drug interactions with strong CYP3A inhibitors.

8. Midostaurin — FLT3 inhibitor
   Use: Added to induction/consolidation for FLT3-mutated AML; sometimes maintenance.
   Mechanism: Blocks FLT3 signaling in mutant blasts.
   Effects: Nausea, rash, QT prolongation (monitor ECG), cytopenias.

9. Gilteritinib — FLT3 inhibitor
   Use: Relapsed/refractory FLT3-mutated AML.
   Mechanism/effects: Potent FLT3 blockade; elevated liver enzymes, differentiation syndrome risk, fatigue.

10. Ivosidenib — IDH1 inhibitor
    Use: IDH1-mutated AML (newly diagnosed unfit or relapsed).
    Mechanism: Restores normal cell differentiation by blocking oncometabolite 2-HG.
    Effects: Differentiation syndrome (emergency steroids if suspected), QT prolongation, LFT rise.

11. Enasidenib — IDH2 inhibitor
    Use: IDH2-mutated relapsed/refractory AML.
    Mechanism/effects: Similar to ivosidenib; differentiation syndrome risk; bilirubin elevation common.

12. Gemtuzumab ozogamicin — anti-CD33 antibody-drug conjugate
    Use: Selected CD33-positive AML, added to chemo or used in low-intensity settings.
    Mechanism: Antibody targets CD33; linked toxin (calicheamicin) kills blasts.
    Effects: Infusion reactions, liver veno-occlusive disease risk, cytopenias.

13. Glasdegib + low-dose cytarabine
    Class: Hedgehog pathway inhibitor with low-dose chemo for unfit adults.
    Mechanism: Targets leukemic stem-cell signaling.
    Effects: Taste changes, muscle spasms, GI upset, cytopenias.

14. Hydroxyurea — ribonucleotide reductase inhibitor
    Use: Short-term cytoreduction for very high white counts while planning therapy.
    Mechanism: Quickly lowers circulating blasts.
    Effects: Cytopenias, mouth sores; temporary measure.

15. Supportive “co-therapies” (briefly):
    Allopurinol or rasburicase to manage uric acid and tumour lysis; antimicrobial prophylaxis (per center protocol); antiemetics; growth-factor support in select windows. These don’t treat AML directly but make treatment safer.

Important: Drug choice depends on age/fitness, gene results, prior therapy, and goals (cure vs disease control). Your team will tailor the plan and dosing.

Dietary molecular supplements

Use only with your oncology team’s approval; check for interactions, bleeding risk, or effects on drug levels.

1. Vitamin D3
   Dose (example): Often 800–2000 IU/day if deficient; guided by blood tests.
   Function/mechanism: Supports immunity, bone health; modulates inflammatory pathways.
   Note: Avoid mega-doses.

2. Omega-3 fatty acids (EPA/DHA)
   Dose: ~1 g/day combined EPA/DHA (food or capsules) unless contraindicated.
   Mechanism: Anti-inflammatory effects; may support appetite and mood.
   Caution: Bleeding risk if platelets are very low.

3. Probiotics (center-specific policy)
   Dose: Food-based (yogurt with live cultures) is often preferred; supplements are not used during profound neutropenia in many centers.
   Mechanism: Gut barrier support; stool regularity.
   Note: Ask your team—safety varies.

4. Oral glutamine (for mucositis support)
   Dose: Protocol-dependent (often divided doses around chemo days).
   Mechanism: Fuel for enterocytes; may ease mouth/GI soreness.
   Note: Only if your team recommends.

5. Zinc (if deficient)
   Dose: Typically 8–11 mg elemental/day; short-term repletion if low.
   Mechanism: Enzyme and immune function.
   Caution: Excess may upset copper balance.

6. Selenium (if deficient)
   Dose: ~50–100 mcg/day from diet or supplements if levels are low.
   Mechanism: Antioxidant selenoproteins.
   Note: Narrow safety window—avoid high doses.

7. Vitamin B12/folate (if deficient)
   Dose: Guided by labs.
   Mechanism: DNA synthesis, red cell production.
   Note: Do not self-supplement high doses without labs.

8. Whey protein or protein shakes
   Dose: 20–30 g protein/day as snack if intake poor.
   Mechanism: Maintains lean mass, wound repair.
   Note: Choose pasteurized, safe products.

9. Electrolyte solutions
   Dose: Small, frequent sips during nausea/diarrhea.
   Mechanism: Prevents dehydration and kidney injury.
   Note: Low sugar options if needed.

10. Multivitamin without megadoses
    Dose: Once daily standard formula if diet is limited.
    Mechanism: Covers small gaps.
    Note: Avoid high-dose antioxidants the week of chemo unless approved.

Immune / regenerative / stem-cell–related” drugs

These are supportive or procedural medicines—not cancer cures on their own. They are used selectively and only under oncology supervision.

1. Filgrastim (G-CSF)
   Dose examples: Daily subcutaneous dosing during recovery windows.
   Function: Stimulates neutrophil production.
   Mechanism: Binds G-CSF receptor on myeloid precursors.
   Note: Not given during certain induction phases unless specific indication.

2. Pegfilgrastim (long-acting G-CSF)
   Dose: Single injection per chemo cycle in appropriate regimens.
   Function/mechanism: Same as G-CSF with longer half-life.
   Caution: Bone pain common.

3. Sargramostim (GM-CSF)
   Function: Broader myeloid stimulation (neutrophils, monocytes).
   Mechanism: GM-CSF receptor activation.
   Use: Select settings; may help recovery after infections.

4. Epoetin alfa or darbepoetin (EPO analogues)
   Function: Supports red cell production in specific anaemia contexts.
   Mechanism: Erythropoietin receptor signaling.
   Note: Use is individualized; not for uncontrolled AML proliferation.

5. Plerixafor (CXCR4 antagonist)
   Function: Mobilizes stem cells from marrow into blood for collection.
   Mechanism: Blocks CXCR4/SDF-1 axis.
   Use: Mainly in transplant stem-cell collection pathways.

6. Allogeneic haematopoietic stem-cell transplant (HSCT) medications
   What this means: A procedure supported by many drugs (conditioning chemo, immunosuppression like tacrolimus, methotrexate, ATG).
   Function: Replace diseased marrow with healthy donor cells; provide graft-versus-leukaemia effect.
   Mechanism: Donor immune system helps clear residual leukaemia.
   Note: Major risks but can be curative in eligible patients.

Procedures/surgeries

1. Allogeneic stem-cell transplant (HSCT)
   Procedure: Conditioning chemo (± radiation), infusion of donor stem cells, close monitoring.
   Why: Offers best chance of long-term control or cure for many high-risk cases.

2. Leukapheresis
   Procedure: Blood is circulated through a machine to remove excess blasts when counts are dangerously high.
   Why: Quickly reduces viscosity and lowers complications while definitive therapy starts.

3. Central venous catheter/port placement
   Procedure: A line inserted into a large vein in the chest/upper arm.
   Why: Safe delivery of chemo, transfusions, and blood draws.

4. Bone marrow biopsy/aspirate
   Procedure: Needle sample from pelvic bone.
   Why: Diagnosis, response assessment, and genetic testing.

5. Splenectomy (rare, selective)
   Procedure: Surgical removal of spleen.
   Why: Considered only for severe hypersplenism (destroying blood cells) or rupture risk; not routine in AML.

Prevention and risk-reduction tips

1. Avoid benzene and solvent exposure; follow workplace safety rules.

2. Do not smoke; seek help to quit if needed.

3. Treat and monitor precursor bone-marrow disorders (like MDS) closely.

4. Keep vaccines current (e.g., influenza, COVID, pneumococcal) when your team says it’s safe.

5. Practice food- and water-safety to prevent infections during low counts.

6. Use sun protection and skin care to maintain barrier health.

7. Maintain healthy weight, activity, and sleep to support immunity.

8. Manage chronic diseases (diabetes, heart disease) to tolerate therapy better.

9. Use protective gear if you work around chemicals or dust.

10. Attend all follow-up visits; early detection of relapse or complications matters.

When to see a doctor now

• Fever ≥38.0°C (100.4°F) once, or any chills/rigors.

• New bleeding, black stools, vomit with blood, or severe nose/gum bleeding.

• Shortness of breath, chest pain, severe headache, confusion, vision change.

• Rapidly worsening fatigue, new rash, painful mouth/throat ulcers.

• Burning with urination, flank pain, or no urine output; severe diarrhea or dehydration.

• Any new symptom that worries you—call your team early.

What to eat” and “what to avoid

Eat (when safe and tolerated):

1. Well-cooked proteins (chicken, fish, eggs), legumes, and tofu.

2. Pasteurized dairy and cheeses; ultra-high-temp milk.

3. Well-washed, peeled or cooked fruits/vegetables.

4. Whole grains, oats, rice, and pasta for steady energy.

5. Small, frequent, calorie- and protein-dense snacks (nut butters, smoothies).

Avoid (especially during low counts):

1. Raw/undercooked meats, eggs, sushi, and unpasteurized products.
2. Salad bars, buffets, or foods sitting at room temperature.
3. Raw sprouts and unwashed berries/leafy greens.
4. Unfiltered well water and ice of unknown safety.
5. Herbal supplements that can interact with chemo (e.g., high-dose turmeric, St. John’s wort) unless approved.

Frequently asked questions

1. Is AML M6 curable?
   Yes, some people can be cured, especially if they respond well to chemotherapy and can receive a suitable stem-cell transplant. Outcomes depend on age, fitness, response to induction, and genetics (e.g., TP53 is higher risk).

2. Why do I need so many blood tests?
   They track counts, organ function, infection markers, and treatment response—essential to keep therapy safe and effective.

3. What is “induction” chemotherapy?
   The first, intense cycle aimed at clearing blasts from blood and marrow to reach remission.

4. What is “consolidation”?
   Follow-up cycles that deepen and maintain remission and prepare for transplant if planned.

5. Do genetics really change treatment?
   Yes. Mutations such as FLT3, IDH1/2, and TP53 guide targeted drugs and transplant decisions.

6. Why might I get a heart test?
   Some AML drugs can stress the heart. Baseline ECG/echo improves safety.

7. Will I lose my hair?
   Often yes with intensive regimens; it grows back after treatment ends.

8. Can I work during treatment?
   Many people reduce or pause work. Fatigue and infection risk make full-time work difficult during induction.

9. What about fertility?
   Some therapies can affect fertility. Ask early about sperm/egg preservation options.

10. Can diet cure AML?
    No. Diet supports strength and healing, but AML needs medical treatment.

11. Should I avoid visitors?
    You can see healthy, vaccinated visitors who follow hand hygiene and masking rules, especially during low counts.

12. Is transplant the only cure?
    Transplant gives the highest chance for many high-risk cases, but some are cured without transplant. Your team will weigh risks and benefits.

13. What is tumour lysis syndrome?
    A rapid breakdown of cancer cells that can strain kidneys and electrolytes. Doctors prevent it with fluids and medicines.

14. How do I know if treatment works?
    Bone marrow tests after induction show if blasts cleared; molecular tests can detect minimal residual disease.

15. What about clinical trials?
    Trials can offer newer therapies. Ask your team about trials suitable for your genetics and stage.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 06, 2025.